Publications by authors named "P Billiald"
In the Americas and specially in Brazil, the Loxosceles intermedia, Loxosceles gaucho and Loxosceles laeta are the three most medically relevant brown spider species, and whose bites can lead to the condition known as loxoscelism. Here, we report the development of a tool capable of identifying a common epitope amongst Loxosceles sp. venom's toxins.
View Article and Find Full Text PDFArticle Synopsis
- GPVI is a part of platelets that helps blood clotting, and scientists are looking at it to create new medicines that could reduce bleeding risks.
- A new treatment called glenzocimab has been studied and it effectively stops GPVI from interacting with substances that help blood clots grow and stay strong.
- Researchers discovered how glenzocimab works by looking at its structure, and they found that it blocks GPVI in a way that prevents it from forming harmful blood clots.
The use of monoclonal antibodies (mAbs) in therapy is gradually advancing and discussions entail its safety, rentability and effectiveness. To this date, around a hundred mAbs have been approved by the FDA for the treatment of various diseases. Aiming for their large-scale production, recombinant DNA technology is mainly employed, and antibodies can be expressed in various eukaryotic and prokaryotic systems.
View Article and Find Full Text PDFArticle Synopsis
- Glenzocimab is a humanized monoclonal antibody fragment targeting a key receptor on platelets, aimed at treating acute ischemic stroke by preventing thrombus growth and stability.
- A phase I study demonstrated that glenzocimab has a dose-proportional pharmacokinetic profile with a two-compartment model, indicating that how the drug behaves in the body is primarily influenced by a person's body weight.
- Simulation results showed that a 1000-mg infusion of glenzocimab significantly reduces platelet aggregation, suggesting potential efficacy, but further studies in stroke patients are needed to confirm its clinical effectiveness.
Envenoming due to spider bites still remains a neglected disease of particular medical concern in the Americas. To date, there is no consensus for the treatment of envenomed patients, yet horse polyclonal antivenoms are usually infused to patients with identified severe medical conditions. It is widely known that venom proteins in the 30-35 kDa range with sphingomyelinase D (SMasesD) activity, reproduce most of the toxic effects observed in loxoscelism.
View Article and Find Full Text PDF